Abstract
The huge molecular radius of immunoglobulins would seem to be a major drawback for the targeting of solid tumors, because of slow extravasation into tumor interstitium and along plasma half-life. The permeability of normal continuous capillary endothelia to intravascular solutes of different molecular sizes has been determined in animals, mainly for macromolecules, and different sources give data consistent with the graph in Fig. 1 (1–3). The position of whole antibodies (IgG, mol wt 150 kDa and effective molecular radius 5.5 nm) is well to the right of albumen (66 kDa and 3.5 nm), and they are therefore very slowly extravasated in normal tissues. A F(ab’)2 fragment (100 kDa, 5.06 nm) should not extravasate much faster than the intact molecule on this basis and a monomeric Fab’ fragment (50 kDa, 3.48 nm) still has quite a high molecular radius (4), so a much smaller molecule would be necessary to equilibrate very quickly with extracellular fluid (ECF).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Garlick, D. G. and Renkin, E. M. (1970) Transport of large molecules from plasma to interstitial fluid and lymph in dogs. Am. J. Physiol. 219, 1595–1605.
Arfors, K.-E., Rutili, G., and Svensjo, E. (1979) Microvascular transport of macromol-ecules in normal and inflammatory conditions. Acta. Physiol. Scand. Suppl. 463, 93–103.
Taylor, A. E. and Granger, D. N. (1984) Exchange of macromolecules across the microcirculation, in Handbook of Physiology, 4th ed. (Eugene, M. and Rekin, C., eds.), Waverly, Baltimore, MD, pp. 467–520.
Pilz, I., Kratky, O., Licht, A., and Sela, M. (1975) Shape and volume of fragments Fab’ and F(ab’)2 of anti-poly (D-alanyl) antibodies in the presence and absence of tetra-D-alanine as determined by small-angle x-ray scattering. Biochemistry 14, 1326–1333.
Covell, D. G., Barbet, J., Holton, O. D., Black, C. D. V., Parker, R. J., and Weinstein J. N. (1986) Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’)2, and Fab’ in mice. Cancer Res. 46, 3969–3978.
Sutherland, R. M., Buchegger, F., Schreyer, M., Vacca, A., and Mach, J. P. (1987) Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellu-lar spheroids. Cancer Res. 47, 1627–1633.
Rowlinson-Busza, G., Deonarain, M. P., and Epenetos, A. A. (1996) Comparison of intact monoclonal antibody, its F(ab’) 2 and Fab fragments and recombinant single chain Fv in a human tumor xenograft model. Tumor Target. 2, 37–48.
Mason, D. W. and Williams, A. F. (1980) The kinetics of antibody binding to membrane antigens in solution and at the cell surface. Biochem. J. 187, 1–20.
Heuser, L. S. and Miller, F. N. (1986) Differential macromolecular leakage from the vasculature of tumors. Cancer 57, 461–464.
Ackerman, N. B. and Hechmer, P. A. (1978) Studies on the capillary permeability of experimental liver metastases. Surg. Gyn. Obstet. 146, 884–888.
Underwood, J. C. E. and Carr, I. (1972) The ultrastructure and permeability characteristics of a transplantable rat sarcoma. J. Pathol. 107, 157–166.
Papadimitriou, J. M. and Woods, A. E. (1975) Structural and functional characteristics of the microcirculation in neoplasms. J. Pathol. 116, 65–72.
Peterson, H.-I., Appelgren, L., Lundborg, G., and Rosengren, B. (1973) Capillary permeability of two transplantable rat tumours as compared with various normal organs of the rat. Bibl. Anat. 12, 511–518.
Gerlowski, L. E. and Jain, R. K. (1986) Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288–305.
Rostock, R. A., Klein, J. L., Kopher, K. A., and Order, S. E. (1984) Variables affecting the tumor localization of 131I-anti-ferritin in experimental hepatoma. Amer. J. Clin. Oncol. 6, 9–18.
Otsuka, F. L. and Fleishman, J. B. (1986) Comparative studies using 125I-and 111In-labeled monoclonal antibodies. Eur. J. Nucl. Med. 11, 295–299.
Badger, C. C., Krohn, K. A., Peterson, A. V., Shulman, H., and Bernstein, I. D. (1985) Experimental radiotherapy of murine lymphoma with 131I-labeled anti-Thy 1. 1 monoclonal antibody. Cancer Res. 45, 1536–1544.
Jakowatz, J. G., Beatty, B. G., Vlahos, W. G., Porudominsky, D., Philben, V. J., Williams, L. E., Paxton, R. J., Shively, J. E., and Beatty, J. D. (1985) High specific activity 111In-labeled anticarcinoembryonic antigen monoclonal antibody: biodistribution and imaging in nude mice bearing human colon cancer xenografts. Cancer Res. 45, 5700–5706.
Rogers, G. T., Harwood, P. J., Pedley, R. B., Boden, J., and Bagshawe, K. D. (1986) Dose-dependent localisation and potential for therapy of F(ab’)2 fragments against CEA studied in a human tumour xenograft model. Br. J. Cancer 54, 341–344.
Washburn, L. C., Sun, T. T., Lee, Y. C., Byrd, B. L., Crook, J. E., and Steplewski, Z. (1987) Y-90-labeled monoclonal antitumour antibodies: effect of purification method and coinjection of unlabeled antibody. J. Nucl. Med. 28, 721.
Sharkey, R. M., Primus, F. J., and Goldenberg, D. M. (1987) Antibody protein dose and radioimmunodetection of GW-39 human colon tumor xenografts. Int. J. Cancer 39(9), 611–617.
Kennel, S. J., Falcioni, R., and Wesley, J. W. (1991) Microdistribution of specific rat monoclonal antibodies to mouse tissues and human tumour xenografts. Cancer Res. 51, 1529–1536.
Boerman, O. C., Sharkey, R. M., Wong, G. Y., Blumenthal, R. D., Aninipot, R. L., and Goldenberg, D. M. (1992) Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. Cancer Immunol. Immunother. 35, 127–134.
Halpern, S. E., Dillman, R. O., Witztum, M. D., Shega, J. F., Hagan, P. L., Burrows, W. M., Dillman, J. B., Clutter, M. L., Sobol, R. E., Frincke, J. M., Bartholomew, R. M., David, G. S., and Carlo, D. J. (1985) Radioimmunodetection of melanoma utilising In-111 96.5 monoclonal antibody: a preliminary report. Radiology 155, 493–499.
Murray, J. L., Rosenblum, M. G., Sobol, R. E., Bartholomew, R. M., Plager, C. E., Haynie, T. P., Jahns, M. F., Glenn, H. J., Lamki, L., Benjamin, R. S., Papadopoulos, N., Boddie, A. W., Frincke, J. M., David, G. S., Carlo, D. J., and Hersh, E. M. (1985) Radioimmunoimaging in malignant melanoma with 111Indium labeled monoclonal antibody 96.5. Cancer Res. 45, 2376–2381.
Carrasquillo, J. A., Bunn, P. A., Keenan, A. M., Reynolds, J. C., Schroff, R. W., Foon, K. A., Ming-Hsu, S., Gazdar, A. F., Mulshine, J. L., Oldham, R. K., Parentesis, P., Horowitz, M., Eddy, J., James, P., and Larson, S. M. (1986) Radioimmunodetection of cutaneous T-cell lymphoma with 111In-labeled T101 monoclonal antibody. N. Engl. J. Med. 315, 673–680.
Eger, R. R., Covell, D. G., Carrasquillo, J. A., Abrams, P. G., Foon, K. A., Reynolds, J. C., Schroff, R. W., Morgan, A. C., Larson, S. M., and Weinstein, J. N. (1987) Kinetic model for the biodistribution of an 111Indium-labeled monoclonal antibody in humans. Cancer Res. 47, 3328–3336.
Murray, J. L., Lamki, L. M., Shanken, L. J., Blake, M. E., Plager, C. E., Benjamin, R. S., Schweighardt, S., Unger, M. W., and Rosenblum, M. G. (1988) Immunospecific saturable clearance mechanisms for Indium-111-labeled anti-melanoma monoclonal antibody 96. 5 in humans. Cancer Res. 48, 4417–4422.
Rosenblum, M. G., Murray, J. L., Lamki, L., David, G., and Carlo, D. (1987) Comparative clinical pharmacology of [111In]-labeled murine monoclonal anti-bodies. Cancer Chemother. Pharmacol. 20, 41–47.
Babaian, R. J., Murray, J. L., Lamki, L. M., Haynie, T. P., Hersh, E. M., Rosenblum, M. G., Glenn, H. J., Unger, M. W., Carlo, D. J., and Von Eschenbach, A. C. (1987) Radioimmunological imaging of metastatic prostate cancer with 111indium-labeled monoclonal antibody PAY 276. J. Urol. 137, 439–443.
Kirkwood, J. M., Neumann, R. D., Zoghbi, S. S., Ernstoff, M. S., Cornelius, E. A., Shaw, C., Ziyadeh, T., Fine, J. A., and Unger, M. W. (1987) Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp 240 antibody (ZME-018). J. Clin. Oncol. 5, 1247–1255.
Abdel-Nabi, H. H., Schwartz, A. N., Goldfogel, G., Ortman-Nabi, J. A., Matsuoka, D. M., Unger, M. W., and Wechter, D. G. (1988) Colorectal tumours: scintigra-phy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings. Radiology 166, 747–752.
Patt, Y. Z., Lamki, L. M., Haynie, T. P., Unger, M. W., Rosenblum, M. G., Shirkhoda, A., and Murray, J. L. (1988) Improved tumour localisation with increasing dose of Indium-111-labeled anti-CEA monoclonal antibody ZCE-025 in metastatic colorectal cancer. J. Clin. Oncol. 6, 1220–1230.
Carrasquillo, J. A., Abrams, P. G., Schroff, R. W., Reynolds, J. C., Woodhouse, C. S., Morgan, A. C., Keenan, A. M., Foon, K. A., Perentis, P., Marshall, S., Horowitz, M., Szymendera, J., Englert, J., Oldham, R. K., and Larson, S. M. (1988) Effect of antibody dose on the imaging and biodistribution of Indium-111 9.2.27 anti-melanoma monoclonal antibody. J. Nucleic Med. 29, 39–47.
Carrasquillo, J. A., Sugarbaker, P., Colcher, D., Reynolds, J. C., Esteban, J., Bryant, G., Keenan, A. M., Perentis, P., Yakoyama, K., Simpson, D. E., Ferroni, P., Farkas, R., Schlom, J., and Larson, S. M. (1988) Radioscintigraphy of colon cancer with iodine-131-labeled B72. 3 monoclonal antibodies. J. Nucleic Med. 29, 1022–1030.
Lamki, L. M., Murray, J. L., Rosenblum, M. G., Patt, Y. Z., Babaian, R., and Unger, M. W. (1988) Effect of unlabeled monoclonal antibody (Moab) on biodistribution of 11 1indium labeled (Moab). Nucleic Med. Commun. 9, 553–564.
Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., Miller, R., Brown, S., Nelp, W. B., Krohn, K. A., Fisher, D., DeSantes, K., Porter, B., Kidd, P., Thomas, E. D., and Bernstein, I. D. (1989) Treatment of refractory non-Hodgkin’ s lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol. 7, 1027–1038.
Griffin, T. W., Bokhari, F., Collino, J., Stochl, M., Bernier, M., Gionet, M., Siebecker, D., Wertheimer, M., Giroves, E. S., Greenfield, L., Houston, L. L., Doherty, P. W., and Wilson, J. (1989) A preliminary pharmacokinetic study of 111In-labeled 260F9 anti-(breast cancer) antibody in patients. Cancer Immunol. Immunother. 29, 43–50.
Serafini, A. N., Goldenberg, D. M., Higinbotham-Ford, E. A., Silberstein, E. B., Van Heertum, R. L., Kotler, J. A., Balasubramanian, N., Garty, I., and Wlodkowski, T. (1989) A multicenter trial of cancer imaging with fragments of CEA monoclonal antibodies. J. Nucl. Med. 82, 748.
Scheinberg, D. A., Straus, D. J., Yeh, S. D., Divgi, C., Gavin-Chesa, P., Graham, M., Pentlow, K., Coit, D., Oettgen, H. F., and Old, L. J. (1990) A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkins lymphoma: effects of tumor burden and antigen expression. J. Clin. Oncol. 8, 792–803.
Steward, M. W. and Steensgaard, J. (1983) Antibody Affinity: Thermodynamic Aspects and Biological Significance. CRC, Boca Raton, FL.
Kennel, S. J., Foote, L. J., Lanford, P. K., Johnson, M., Mitchell, T., and Braslawsky, G. R. (1983) Direct binding of radio-iodinated monoclonal antibody to tumour cells: significance of antibody purity and affinity for drug targeting or tumour imaging. Hybridoma 2, 297–310.
Devey, M. E. and Steward, M. W. (1988) The role of antibody affinity in the performance of solid phase assays, in Elisa and Other Solid Phase Immunoassays (Kemeny, D. M. and Chollacombe, S. J., eds.), Wiley, UK, pp. 135–153.
Weinstein, J. N., Covell, D. G., Barbet, J., Eger, R. R., Holton, O. D., Talley, M. J., Parker, R. J., and Black, C. D. V. (1987) Local and cellular factors in the phar-macology of monoclonal antibodies, in Membrane Mediated Cytotoxicity (Bonavida, B. and Collier, R. J., eds.), Liss, New York, pp. 279–289.
Sharkey, R. M., Primus, F. J., Shochat, D., and Goldenberg, D. M. (1988) Comparison of tumour targeting of mouse monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human tumour-hamster host model. Cancer Res. 48, 1823–1828.
Wang, A.-C., Banjo, C., Fuks, A., Shuster, J., and Gold, P. (1976) Heterogeneity of the protein moiety of carcinoembryonic antigens. Immunol. Commun. 5, 205–210.
Olson, W. C., Spitznagel, T. M., and Yarmush, M. L. (1989) Dissociation kinetics of antigen-antibody interactions: studies on a panel of anti-albumin monoclonal antibodies. Mol. Immunol. 26, 129–136.
Watt, R. M., Herron, J. M., and Voss, E. W. (1980) First order dissociation rates between a subpopulation of high-affinity rabbit anti-fluorescyl IgG antibody and homologous ligand. Mol. Immunol. 17, 1237–1243.
Morrison, J. F. and Walsh, C. T. (1988) The behaviour and significance of slow-binding enzyme inhibitors. Adv. Enzymol. 61, 201–301.
Aisen, P. and Leibman, A. (1978) Thermodynamic and accessibility factors in the specific binding of iron to human transferrin, in Transport by Proteins (Blauer, G. and Sund, H., eds.), Walter de Gruyter, Berlin, pp. 277–294.
Green, N. M. (1963) Avidin. The nature of the biotin-binding site. Biochem. J. 89, 599–609.
Absolom, D. R. and van Oss, C. J. (1986) The nature of the antigen-antibody bond and the factors affecting its association and dissociation. CRC Crit. Rev. Immunol. 6, 1–46.
Thomas, G. D., Chappell, M. J., Dykes, P. W., Ramsden, D. B., Godfrey, K. R., Ellis, J. R. M., and Bradwell, A. R. (1989) Effect of dose, molecular size, affinity, and protein binding on tumour uptake of antibody or ligand: a biomathematical model. Cancer Res. 49, 3290–3296.
Chappell, M. J., Thomas, G. D., Godfrey, K. R., and Bradwell, A. R. (1991) Optimal tumour targeting by antibodies: development of a mathematical model. J. Pharmacokin Biopharm. 19, 227–260.
Jacquez, J. A. (1985) Compartmental Analysis in Biology and Medicine, University of Michigan Press, Ann Arbor, MI.
Shampine, L. F. and Gear, C. W. (1979) A user’s view of solving stiff differential equations. SIAM Rev. 21, 1–17.
Fatunla, S. O. (1988) Numerical Methods for Initial Value Problems in Ordinary Differential Equations. Academic, New York.
Chappell, M. J. and Godfrey, K. R. (1990) Structural identifiability of a model developed for optimal tumour targeting by antibodies using the similarity transformation approach. University of Warwick Control and Instrument Systems Centre, Report No. 7.
Curtis, A. R. and Sweetenham, W. P. (1987) FACSIMILE/CHEKMAT User’s Manual. Harwell Laboratory Report, UK Atomic Energy Authority, Atomic Energy Research Establishment, Computer Science and Systems Division, 12805.
Attard, A. R., Chappell, M. J., Bennett, J., Thomas, G. D., Godfrey, K. R., Dykes, P. W., and Bradwell, A. R. (1991) Optimal tumor targeting by antibodies: Validation of a mathematical model. Antibody Immunoconj. Radiopharmaceu. 4, 435–441.
Thomas, G. D. (1995) Development of a model of tumour targeting to predict optimal conditions for therapy. MD Thesis, University of London, London.
Bhat, T. N., Bentley, G. A., Fischmann, T. O., Boulot, G., and Poljak, R. J. (1990) Small rearrangements in structures of Fv and Fab fragments of antibody D1. 3 on antigen binding. Nature 347, 483–485.
Cheong, H. S., Chang, J. S., Park, J. M., and Byun, S. M. (1990) Affinity enhancement of bispecific antibody against two different epitopes in the same antigen. Biochem. Biophys. Res. Commun. 173, 795–800.
Ehrlich, P. H., Moyle, W. R., Moustafa, Z. A., and Canfield, R. E. (1982) Mixing two monoclonal antibodies yields enhanced affinity for antigen. J. Immunol. 128, 2709–2713.
Holmes, N. J. and Parham, P. (1983) Enhancement of monoclonal antibodies against HLA-A2 is due to antibody bivalency. J. Biol. Chem. 258, 1580–1586.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Thomas, G.D. (2000). Effect of Dose, Molecular Size, and Binding Affinity on Uptake of Antibodies. In: Francis, G.E., Delgado, C. (eds) Drug Targeting. Methods in Molecular Medicine™, vol 25. Humana Press. https://doi.org/10.1385/1-59259-075-6:115
Download citation
DOI: https://doi.org/10.1385/1-59259-075-6:115
Publisher Name: Humana Press
Print ISBN: 978-0-89603-531-7
Online ISBN: 978-1-59259-075-9
eBook Packages: Springer Protocols